(Q34836649)

4 August 2017

Angiotensin blockade in late autosomal dominant polycystic kidney disease (English)

1 reference

autosomal dominant polycystic kidney disease

4 August 2017

0 references

autosomal dominant polycystic kidney

1 reference

inferred from title

author

Robert William Schrier

4

object named as

Robert W Schrier

1 reference

4 August 2017

11

Dana C Miskulin

1 reference

4 August 2017

Vicente E Torres

1

1 reference

4 August 2017

Kaleab Z Abebe

2

1 reference

4 August 2017

Arlene B Chapman

3

1 reference

4 August 2017

William E Braun

5

1 reference

4 August 2017

Theodore I Steinman

6

1 reference

4 August 2017

Franz T Winklhofer

7

1 reference

4 August 2017

Godela Brosnahan

8

1 reference

4 August 2017

Peter G Czarnecki

9

1 reference

4 August 2017

Marie C Hogan

10

1 reference

4 August 2017

Frederic F Rahbari-Oskoui

12

1 reference

4 August 2017

Jared J Grantham

13

1 reference

4 August 2017

Peter C Harris

14

1 reference

4 August 2017

Michael F Flessner

15

1 reference

4 August 2017

Charity G Moore

16

1 reference

4 August 2017

Ronald D Perrone

17

1 reference

4 August 2017

HALT-PKD Trial Investigators

18

1 reference

4 August 2017

language of work or name

English

0 references

publication date

15 November 2014

1 reference

The New England Journal of Medicine

4 August 2017

1 reference

4 August 2017

371

1 reference

4 August 2017

24

1 reference

4 August 2017

2267-2276

1 reference

Blood pressure in early autosomal dominant polycystic kidney disease

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

The HALT polycystic kidney disease trials: design and implementation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Clinical practice. Autosomal dominant polycystic kidney disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Telmisartan, ramipril, or both in patients at high risk for vascular events

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Shared parameter models for the joint analysis of longitudinal data and event times

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Group sequential procedures: calendar versus information time

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Combined angiotensin inhibition for the treatment of diabetic nephropathy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Everolimus in patients with autosomal dominant polycystic kidney disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

No effect of enalapril on progression in autosomal dominant polycystic kidney disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Dual renin-angiotensin system blockade at optimal doses for proteinuria

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284824

Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease

26 October 2018

1 reference

12 December 2020

The anatomy of the renin-secreting cell in adult polycystic kidney disease

1 reference

12 December 2020

Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease

1 reference

12 December 2020

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group

1 reference

12 December 2020

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

12 December 2020

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1402686

1 reference

4 August 2017

1 reference

4 August 2017

1 reference